Total Payments
$196,233
2024 Payments
$15,146
Companies
37
Transactions
483
Medicare Patients
12,108
Medicare Billing
$828,380
Payment Breakdown by Category
Other$171,937 (87.6%)
Food & Beverage$8,795 (4.5%)
Consulting$8,572 (4.4%)
Travel$6,698 (3.4%)
Education$231.85 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $171,937 | 54 | 87.6% |
| Food and Beverage | $8,795 | 384 | 4.5% |
| Consulting Fee | $8,572 | 12 | 4.4% |
| Travel and Lodging | $6,698 | 27 | 3.4% |
| Education | $231.85 | 6 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $124,250 | 107 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $36,231 | 58 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $14,577 | 73 | $0 (2023) |
| Lilly USA, LLC | $8,514 | 12 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $6,549 | 45 | $0 (2024) |
| PFIZER INC. | $3,072 | 30 | $0 (2024) |
| Amgen Inc. | $638.39 | 47 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $382.77 | 3 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $379.81 | 37 | $0 (2023) |
| Abbott Laboratories | $259.76 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,146 | 22 | Novo Nordisk Inc ($14,843) |
| 2023 | $47,258 | 62 | Novo Nordisk Inc ($46,683) |
| 2022 | $62,760 | 72 | Novo Nordisk Inc ($62,422) |
| 2021 | $249.37 | 19 | Amgen Inc. ($40.42) |
| 2020 | $4,435 | 27 | E.R. Squibb & Sons, L.L.C. ($3,616) |
| 2019 | $11,817 | 81 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,431) |
| 2018 | $10,347 | 61 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,134) |
| 2017 | $44,221 | 139 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21,493) |
All Payment Transactions
483 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 11/18/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,100.00 | General |
| Category: Diabetes | ||||||
| 10/07/2024 | Azurity Pharmaceuticals, Inc. | EDARBYCLOR (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/04/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 09/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Obesity | ||||||
| 08/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/30/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Obesity | ||||||
| 07/29/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.47 | General |
| 06/10/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $33.67 | General |
| Category: Coronary | ||||||
| 06/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: Obesity | ||||||
| 05/24/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $8.75 | General |
| Category: Heart Failure and Hypertension | ||||||
| 05/08/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,037.50 | General |
| 05/08/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $104.23 | General |
| 05/08/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $20.10 | General |
| 04/29/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 04/17/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $9.70 | General |
| Category: Heart Failure and Hypertension | ||||||
| 04/02/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 04/01/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,636.00 | General |
| Category: Diabetes | ||||||
| 03/08/2024 | Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 02/05/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Diabetes | ||||||
| 01/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Cardiology | ||||||
| 12/19/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: Diabetes | ||||||
| 12/19/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $2.18 | General |
| Category: Diabetes | ||||||
| 12/18/2023 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,684 | 3,521 | $837,091 | $214,677 |
| 2022 | 25 | 3,450 | 4,303 | $850,031 | $215,448 |
| 2021 | 24 | 3,082 | 3,932 | $795,044 | $210,026 |
| 2020 | 25 | 2,892 | 3,735 | $776,309 | $188,228 |
Total Patients
12,108
Total Services
15,491
Medicare Billing
$828,380
Procedure Codes
101
All Medicare Procedures & Services
101 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 497 | 668 | $242,484 | $66,747 | 27.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 246 | 460 | $224,020 | $66,587 | 29.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 380 | 384 | $92,928 | $19,929 | 21.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 214 | 220 | $53,240 | $12,034 | 22.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 568 | 812 | $47,908 | $9,141 | 19.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 43 | $31,519 | $6,042 | 19.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 52 | $17,836 | $5,226 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $23,693 | $5,132 | 21.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $20,730 | $4,921 | 23.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 12 | 25 | $18,150 | $4,529 | 25.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 367 | 427 | $17,080 | $2,851 | 16.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 39 | $9,360 | $2,577 | 27.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 29 | $7,163 | $2,013 | 28.1% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 21 | 22 | $7,920 | $1,895 | 23.9% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 15 | 16 | $5,872 | $1,391 | 23.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $5,388 | $1,223 | 22.7% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 22 | 22 | $1,958 | $482.68 | 24.7% |
| 85610 | Blood test, clotting time | Office | 2023 | 12 | 105 | $3,675 | $441.00 | 12.0% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 20 | 20 | $1,620 | $398.20 | 24.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 13 | 18 | $1,350 | $379.26 | 28.1% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 21 | 22 | $1,342 | $330.44 | 24.6% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 19 | 19 | $931.00 | $212.94 | 22.9% |
| 93790 | Ambulatory blood pressure monitoring, 1 day or longer, with review, interpretation and report | Office | 2023 | 11 | 11 | $682.00 | $138.06 | 20.2% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 21 | 22 | $242.00 | $57.20 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 226 | 400 | $194,800 | $60,004 | 30.8% |
About Dr. David Powell, MD
Dr. David Powell, MD is a Cardiovascular Disease healthcare provider based in Springfield, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1013902477.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Powell, MD has received a total of $196,233 in payments from pharmaceutical and medical device companies, with $15,146 received in 2024. These payments were reported across 483 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($171,937).
As a Medicare-enrolled provider, Powell has provided services to 12,108 Medicare beneficiaries, totaling 15,491 services with total Medicare billing of $828,380. Data is available for 4 years (2020–2023), covering 101 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Springfield, NJ
- Active Since 09/13/2005
- Last Updated 05/09/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1013902477
Products in Payments
- Ozempic (Drug) $50,717
- JARDIANCE (Drug) $39,208
- Rybelsus (Drug) $17,494
- ELIQUIS (Drug) $17,405
- ENTRESTO (Drug) $6,291
- PRADAXA (Drug) $5,393
- Repatha (Biological) $381.33
- XARELTO (Drug) $379.81
- MULTAQ (Drug) $364.85
- Corlanor (Drug) $257.06
- COSENTYX (Biological) $217.85
- AMPLATZER Occluders (Device) $197.03
- Kerendia (Drug) $156.43
- VYNDAQEL (Drug) $131.19
- LOKELMA (Drug) $100.00
- Vascepa (Drug) $95.68
- Hillrom - Cardiac Ambulatory Monitor (Device) $93.58
- PRALUENT (Biological) $88.18
- WATCHMAN (Device) $88.05
- Wegovy (Drug) $84.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Springfield
Tony De Martini, M.d, M.D
Cardiovascular Disease — Payments: $519,196
Cardiovascular Disease $519,196
Dr. Gerard Oghlakian, Md, MD
Cardiovascular Disease — Payments: $502,096
Cardiovascular Disease $502,096
Robert Fishberg, Md, MD
Cardiovascular Disease — Payments: $171,370
Cardiovascular Disease $171,370
Dr. Shady Henien, M.d, M.D
Cardiovascular Disease — Payments: $104,402
Cardiovascular Disease $104,402
Dr. Shang-Chiun Lee, Md, MD
Cardiovascular Disease — Payments: $97,193
Cardiovascular Disease $97,193
Jack Hall, Md, MD
Cardiovascular Disease — Payments: $88,257
Cardiovascular Disease $88,257